Stryker launches InSpace, a biodegradable subacromial balloon implant

Stryker announced the launch of InSpace, a balloon implant for arthroscopic treatment of massive irreparable rotator cuff tears (MIRCTs)*, in India. MIRCTs are one of the most common causes of shoulder dysfunction. InSpace provides a new option for surgeons in their shoulder continuum of care that allows them to better meet the needs of their patients. 

The InSpace balloon implant is designed to restore the subacromial space without requiring sutures or fixation devices and has been demonstrated to improve shoulder motion and function.

The InSpace balloon implant has a long successful clinical history of over 14 years, 35 peer-reviewed clinical articles, and 41,000 balloons implanted across the globe. 

Some of the clinically proven advantages of InSpace are:

• Less invasive, streamlined surgical solution for MIRCTs compared to other surgical treatment options that require fixation devices or grafts.
• Early, clinically meaningful improvement in shoulder motion and function. 
• On average, patients showed an increase in range of motion compared to partial repair patients following surgery.
• Demonstrated comparable long-term safety and effectiveness results (compared to partial repair) out to two years.
• Patients demonstrated a high likelihood of clinical success, greater than 87 per cent at two years, in subjects 65 and over.

*The InSpace subacromial tissue spacer system is indicated for the treatment of patients with massive, irreparable full-thickness torn rotator cuff tendons due to trauma or degradation with mild to moderate gleno-humeral osteoarthritis in patients greater than or equal to 65 years of age whose clinical conditions would benefit from treatment with a shorter surgical time compared to partial rotator cuff repair.